ARCHIVES

Top Management Shifts At Bristol-Myers Squibb Oncology, R&D Units

This article is from The Cancer Letter archive.

Vol. 21 No. 38 | October 6, 1995

Download PDF Visit The Full Archive

Related Articles

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008

ACS To Accept Database On Method Of Unconventional Rx

November 26, 1993

Feral Mouse Colony Recompetition Given Concept Approval

November 16, 1990

New Missouri Center Seeing a Director

July 16, 1982

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006